Investors Buy Shares of Bristol-Myers Squibb (BMY) on Weakness

Investors purchased shares of Bristol-Myers Squibb Co (NYSE:BMY) on weakness during trading on Monday. $185.64 million flowed into the stock on the tick-up and $109.43 million flowed out of the stock on the tick-down, for a money net flow of $76.21 million into the stock. Of all stocks tracked, Bristol-Myers Squibb had the 7th highest net in-flow for the day. Bristol-Myers Squibb traded down ($0.02) for the day and closed at $68.96

BMY has been the subject of a number of analyst reports. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Wednesday, October 25th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Piper Jaffray Companies reissued a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Credit Suisse Group reissued a “hold” rating and set a $61.00 target price (up previously from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $66.73.

The company has a market capitalization of $110,230.00, a P/E ratio of 28.54, a P/E/G ratio of 2.14 and a beta of 1.08. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter in the previous year, the company earned $0.63 earnings per share. The company’s quarterly revenue was up 3.9% on a year-over-year basis. analysts anticipate that Bristol-Myers Squibb Co will post 3.21 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.38%. The ex-dividend date of this dividend was Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is currently 67.80%.

In related news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II acquired 4,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were acquired at an average cost of $62.30 per share, with a total value of $249,200.00. Following the purchase, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Delphi Private Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $108,000. Atlantic Trust LLC purchased a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at approximately $111,000. Massey Quick Simon & CO. LLC grew its stake in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares during the period. NuWave Investment Management LLC purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $119,000. Finally, Blue Chip Partners Inc. grew its stake in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the period. 69.82% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Investors Buy Shares of Bristol-Myers Squibb (BMY) on Weakness” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://ledgergazette.com/2018/02/21/investors-buy-shares-of-bristol-myers-squibb-bmy-on-weakness.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply